157 related articles for article (PubMed ID: 31755463)
1. Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy.
Chang M; Lally SE; Dalvin LA; Orloff MM; Shields CL
Indian J Ophthalmol; 2019 Dec; 67(12):2071-2073. PubMed ID: 31755463
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Conjunctival Squamous Cell Carcinoma with Orbital Extension.
Demirci H; Elner VM; Demirci FY; Robinson DR; Chinnaiyan A; Schlachter D; Joseph S; Worden F
Ophthalmology; 2021 May; 128(5):801-804. PubMed ID: 32980395
[No Abstract] [Full Text] [Related]
3. Pembrolizumab for Recurrent Conjunctival Melanoma.
Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
[No Abstract] [Full Text] [Related]
4. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
Ford J; Thuro BA; Thakar S; Hwu WJ; Richani K; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2017; 33(4):e82-e85. PubMed ID: 27662198
[TBL] [Abstract][Full Text] [Related]
7. Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma.
Stauner CT; Drexler K; Berneburg M; Haferkamp S
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1376-1378. PubMed ID: 30299577
[No Abstract] [Full Text] [Related]
8. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival Melanoma Metastasis to the Contralateral Orbit.
He F; Wang Y; Jia R
J Craniofac Surg; 2018 Nov; 29(8):2128-2130. PubMed ID: 29894459
[TBL] [Abstract][Full Text] [Related]
10. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.
Shields CL; Shields JA; Gündüz K; Cater J; Mercado GV; Gross N; Lally B
Arch Ophthalmol; 2000 Nov; 118(11):1497-507. PubMed ID: 11074806
[TBL] [Abstract][Full Text] [Related]
11. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.
Shields CL
Trans Am Ophthalmol Soc; 2000; 98():471-92. PubMed ID: 11190037
[TBL] [Abstract][Full Text] [Related]
12. Malignant melanoma of the lacrimal drainage apparatus complicating conjunctival melanoma.
Satchi K; McKelvie P; McNab AA
Ophthalmic Plast Reconstr Surg; 2015; 31(3):207-10. PubMed ID: 25126770
[TBL] [Abstract][Full Text] [Related]
13. Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review.
Alhammad FA; Alburayk KB; Albadri KS; Butt SA; Azam F
Orbit; 2024 Feb; 43(1):49-57. PubMed ID: 37052129
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma.
Schvartsman G; Perez K; Sood G; Katkhuda R; Tawbi H
Ann Intern Med; 2017 Sep; 167(5):361-362. PubMed ID: 28761949
[No Abstract] [Full Text] [Related]
15. Melanoma of the Palpebral Conjunctiva and Eyelid.
Zhang P; Chen L
N Engl J Med; 2022 Mar; 386(12):e28. PubMed ID: 35302723
[No Abstract] [Full Text] [Related]
16. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
17. Conjunctival metastasis from a cutaneous melanoma as the initial sign of dissemination.
Kwapiszeski BR; Savitt ML
Am J Ophthalmol; 1997 Feb; 123(2):266-8. PubMed ID: 9186141
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody.
Yamashita C; Otsuka A; Nomura M; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e92-e93. PubMed ID: 30199578
[No Abstract] [Full Text] [Related]
19. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
20. Nasal and orbital recurrence of conjunctival melanoma 21 years after exenteration.
Paridaens AD; McCartney AC; Lavelle RJ; Hungerford JL
Br J Ophthalmol; 1992 Jun; 76(6):369-71. PubMed ID: 1622950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
